The Chinese biopharmaceutical contract manufacturing market is estimated to be worth USD 2.6 billion

COMMERCE CITY, Colo. - July 10, 2020 - PRLog -- The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of companies offering contract manufacturing services for biopharmaceuticals in China.

§  An analysis of the partnerships that have been established in this domain, in the recent past.

§  An analysis of the expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, in the recent past.

§  A detailed analysis of more than 1500 clinical trials related to biopharmaceuticals that have been / are being / are likely to be conducted in China.

§  An estimate of the overall, installed capacity for manufacturing biopharmaceuticals, based on data reported by industry stakeholders in the public domain.

§  An analysis of the initiatives of big biopharma players engaged in this domain.

§  A qualitative analysis, highlighting the various factors that need to be taken into consideration by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

§  Detailed profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biopharmaceutical products.

§  A case study comparing the key characteristics of large molecule and small molecule drugs.

§  A discussion on industry affiliated trends, key drivers, and challenges, under a SWOT framework, which are likely to impact the evolution of this field.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

• Type of Product

§  API

§  FDF

• Type of Expression System Used

§  Mammalian

§  Microbial

§  Others

• Scale of Operation

§  Preclinical / Clinical

§  Commercial

• Size of Manufacturer

§  Small

§  Mid-sized

§  Large / Very Large

• Type of Biologic

§  Antibody

§  Vaccine

§  Others

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

Other Recent Offerings

1.      China Pharmaceutical Contract Manufacturing Services Market, 2020-2030 (https://www.rootsanalysis.com/reports/view_document/china...)

2.      Live Biotherapeutics Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030 (https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html)

3.      Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030 (https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html)


Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com